Humana Inc.
HUM
NYSE·Healthcare·Medical - Healthcare Plans·Mkt cap $48.2B
$401.54
▼ -1.23%
P/E
37.77
Mkt Cap
$48.2B
52-Wk Range
$163.11–$428.88
52-Week Range
$163.11 - $428.88
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 29.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive Healthcare Network
- Government Contract Expertise
- Comprehensive Service Portfolio
- Advanced Healthcare Technology
Bear Case
2 risks
- Low volatility (beta 0.7).
- High premium - requires strong execution
Growth
Moderate growth ahead
Aging Population Demographics
Value
High premium - requires strong execution
Momentum
Strong
+12.8% over 3m
Quality
Thin
Excellent business quality
Dividend
Modest
0.88% yield
Smart-money signal
Who's buying HUM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 29, 2026
Reported EPS of $7.61 vs $7.27 consensus (+4.7% surprise). Revenue of $40.9B vs $40.6B expected (+0.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+4.7%
Revenue trend · last 8Q
—
+10%
+8%
+10%
+11%
+11%
+23%
+26%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$29.4B
$29.2B
$32.1B
$32.4B
$32.6B
$32.5B
$39.6B
$40.9B
Margins · last 8Q
Gross
-14.5%
Operating
3.8%
Profit
1.7%
Wall Street consensus
23 analysts · 39% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
39%
Hold
57%
Sell
4%
Median Price Target
—
Latest: Guggenheim · Jul 30, 2026
vs Industry
How HUM stacks vs Medical - Healthcare Plans
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related